Literature DB >> 11160629

Drug interactions with the dopamine transporter in cryopreserved human caudate.

A J Eshleman1, K Wolfrum, D C Mash, K Christensen, A Janowsky.   

Abstract

Although several model systems have been developed to characterize the function of the dopamine transporter (DAT), there is a relative lack of data regarding dopamine (DA) uptake by human caudate, as contrasted to binding studies. Cryopreserved human brain tissue can be used for functional as well as radioligand binding studies of neuronal proteins. The drug-induced inhibition of [125I]RTI-55 binding to, and [3H]DA uptake by, cryopreserved human caudate preparations has now been characterized. Using human caudate membranes, a single site for [125I]RTI-55 binding was observed in association and saturation experiments. The relative potencies of 22 drugs for inhibition of [125I]RTI-55 binding to membranes prepared from cryopreserved human caudate, fresh rat striatum, and HEK293 cells expressing the recombinant human DAT (HEK-hDAT) were highly correlated. The affinity of DA for the DAT, as measured by [3H]DA uptake experiments, was higher in both the cryopreserved human caudate and freshly prepared rat striatum than in HEK-hDAT cells. Although affinities were similar in rat and human brain tissue preparations, the maximal uptake rate in the cryopreserved human caudate was approximately 1 to 4% and 7% of the rate in fresh and cryopreserved rat striatal preparations, respectively. The relative potencies of 22 drugs for inhibition of [3H]DA uptake were similar for tissue prepared from cryopreserved human caudate, nonfrozen rat striatum, and intact HEK-hDAT cells. These data suggest that cryopreserved human caudate can be used to characterize drug interactions with the DAT, and that HEK-hDAT cells provide a comparable system for modeling the initial interaction of drugs with native hDAT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160629

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.

Authors:  Piotr Popik; Martyna Krawczyk; Krystyna Golembiowska; Gabriel Nowak; Aaron Janowsky; Phil Skolnick; Arnold Lippa; Anthony S Basile
Journal:  Cell Mol Neurobiol       Date:  2006-04-25       Impact factor: 5.046

2.  Development of stereotyped behaviors during prolonged escalation of methamphetamine self-administration in rats.

Authors:  Martin Hadamitzky; Stanley McCunney; Athina Markou; Ronald Kuczenski
Journal:  Psychopharmacology (Berl)       Date:  2012-04-20       Impact factor: 4.530

3.  Measurement of plasmalemmal dopamine transport, vesicular dopamine transport, and K(+)-stimulated dopamine release in frozen rat brain tissue.

Authors:  Trent J Volz; Sarah J Farnsworth; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurosci Methods       Date:  2009-03-28       Impact factor: 2.390

4.  Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes.

Authors:  Benjamin B Gelman; Trung P Nguyen
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-20       Impact factor: 4.147

5.  Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists.

Authors:  Steven P Presgraves; Tariq Ahmed; Sabine Borwege; Jeffrey N Joyce
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.978

6.  Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.

Authors:  Jeffrey N Joyce; Cheryl Woolsey; Han Ryoo; Sabine Borwege; Diane Hagner
Journal:  BMC Biol       Date:  2004-10-11       Impact factor: 7.431

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.